FIELD: medicine.
SUBSTANCE: blood serum Gleevec concentrations in the patients suffering chronic myeloid leukemia treated by the first-generation tyrosine kinase inhibitor Gleevec is estimated by high-efficiency liquid chromatography with tandem mass spectrometry. If observing the low Gleevec concentration 998.15±115.7 ng/ml, the therapy of chronic myeloid leukemia is considered to be ineffective, and a complete cytogenetic response appears not to be reached; the high Gleevec concentration being 1475.15±95.5 ng/ml enables the clinical effectiveness in chronic myeloid leukemia in a combination with reaching the complete cytogenetic response.
EFFECT: method allows for increasing the estimating accuracy of the clinical effectiveness.
4 ex, 1 tbl, 2 dwg
